Skip to main content
Top

Open Access 08-05-2025 | Heart Failure | Original Research

Association Between Type 2 Diabetes Mellitus and Heart Failure: A Retrospective Study from a Tertiary Care Diabetes Centre in India

Authors: Rajendra Pradeepa, Thyparambil Aravindakshan PramodKumar, Ranjit Mohan Anjana, Saravanan Jebarani, Abdul Subhan Naziyagulnaaz, Sadasivam Ganesan, Natrajan Premanand, Abraham Oomman, Soumitra Kumar, Pathiyil Balagopalan Jayagopal, Gurpreet Singh Wander, Ajit Mullasari, Jagat Narula, Sanjay Jain, Onkar C. Swami, Viswanathan Mohan

Published in: Diabetes Therapy

Login to get access

Abstract

Introduction

The study aimed to explore the association between type 2 diabetes (T2D) and heart failure (HF) using echocardiography and NT-proBNP. The study also derived an NT-proBNP cut-off for diagnosing HF by echo in Asian Indians with T2D.

Methods

A retrospective study was performed using data from individuals with T2D, aged ≥ 18 years, who visited diabetes clinics in India between March 2019 and December 2023. NT-proBNP levels were quantified by chemiluminescence, and left ventricular ejection fraction (LVEF) was assessed from echo using two-dimensional (2D) echocardiography. Heart failure was classified based on the European Society of Cardiology (ESC) guidelines. Receiver operating characteristic (ROC) curve was performed to determine the optimal NT-proBNP cut-off for diagnosing HF by echo.

Results

Among the 1189 study individuals included in the study (714 men and 475 women), 5.9% were identified as having HF with reduced ejection fraction (HFrEF), 5.5% had mildly reduced ejection fraction (HFmrEF), and 14.1% had HF with preserved ejection fraction (HFpEF) while the rest (74.5%) had LVEF > 50%. Elevated NT-proBNP levels were observed in those with reduced ejection fraction. ROC analysis identified an optimal NT-proBNP threshold of 398 pg/mL for diagnosing HF, with 87% sensitivity and 78% specificity. HF prevalence increased with age, peaking at 30.6% in individuals aged 61–70 years. Women with HF had higher NT-proBNP levels than men.

Conclusions

In this diabetes clinic population, 11.5% of individuals with T2D had moderate to reduced LVEF. Early identification of HF using echocardiography and NT-proBNP in a diabetes clinic could help improve prognosis.
Appendix
This content is only visible if you are logged in and have the appropriate permissions.
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
Association Between Type 2 Diabetes Mellitus and Heart Failure: A Retrospective Study from a Tertiary Care Diabetes Centre in India
Authors
Rajendra Pradeepa
Thyparambil Aravindakshan PramodKumar
Ranjit Mohan Anjana
Saravanan Jebarani
Abdul Subhan Naziyagulnaaz
Sadasivam Ganesan
Natrajan Premanand
Abraham Oomman
Soumitra Kumar
Pathiyil Balagopalan Jayagopal
Gurpreet Singh Wander
Ajit Mullasari
Jagat Narula
Sanjay Jain
Onkar C. Swami
Viswanathan Mohan
Publication date
08-05-2025
Publisher
Springer Healthcare
Published in
Diabetes Therapy
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-025-01746-3

Keynote series | Spotlight on managing health in obesity

Obesity is a major contributor to cardiorenal metabolic disease, but its impact extends throughout the body. Understand how obesity can affect other organ systems and impact treatment, and whether weight-loss measures improve outcomes.

Prof. Eva L. Feldman
Prof. Jonette Keri
Developed by: Springer Medicine
Watch now
Video

Women’s health knowledge hub

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Read more

Keynote webinar | Spotlight on advances in lupus

  • Live
  • Webinar | 27-05-2025 | 18:00 (CEST)

Systemic lupus erythematosus is a severe autoimmune disease that can cause damage to almost every system of the body. Join this session to learn more about novel biomarkers for diagnosis and monitoring and familiarise yourself with current and emerging targeted therapies.

Join us live: Tuesday 27th May, 18:00-19:15 (CEST)

Prof. Edward Vital
Prof. Ronald F. van Vollenhoven
Developed by: Springer Medicine
Register now
Webinar